Drugs / 2-[ 1-hexyloxyethel]-2-devinyl Pyropheophorbide-a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01668823 | Feb 2004 → Jun 2013 | lung adenocarcinoma, lung carcinoma in situ, lung large cell carcinoma, squamous cell lung carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-[ 1-hexyloxyethel]-2-devinyl Pyropheophorbide-a | “A Phase I Study of Light Dose for Photodynamic Therapy(PDT) Using 2-[ 1-hexyloxyethel]-2-devinyl Pyropheophorbide-a (HPPH) for Treatment of Non-small Cell Carcinoma in Situ or...” NCT01668823 ↗ |
| Known as | HPPH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01668823 ↗ |
| Route | Intravenous | “Patients receive HPPH intravenously (IV) over 1 hour on day 1.” NCT01668823 ↗ |